胃癌内镜切除术后长期生存:多中心前瞻性队列的真实世界证据
该多中心前瞻性队列分析了2010年7月至2012年6月接受内镜切除的9054例患者共10021处早期胃癌的长期结局。5年总生存率为89.0%(95%CI 88.3%-89.6%),各病理治愈性分级(A2、A3、B)与A1相比全因死亡风险无显著差异,所有分级5年总生存率95%CI下限均超过预设阈值5年总生存率。结论认为内镜切除可作为符合A1、A2、A3和B级早期胃癌的标准治疗。
要点
- 9054例早期胃癌患者内镜切除后5年总生存率为89.0%(95%CI 88.3%-89.6%)。
- A2、A3、B级与A1级相比全因死亡风险无显著差异。
- 所有病理治愈性分级5年总生存率95%CI下限均超过阈值5年总生存率。
核心结论
- 内镜切除可作为符合A1、A2、A3和B级早期胃癌患者的标准治疗。
研究设计与样本
- 多中心前瞻性队列研究,纳入2010年7月至2012年6月接受内镜切除的9054例患者共10021处早期胃癌。
主要发现
- 总体5年总生存率为89.0%(95%CI 88.3%-89.6%)。
- 多因素分析中,A2、A3、B级与A1级相比全因死亡风险无显著差异。
- 所有病理治愈性分级5年总生存率95%CI下限均超过阈值5年总生存率。
关键数值与推荐
- A1级:分化型、pT1a、无溃疡、≤2 cm。
- A2级:分化型、pT1a、无溃疡且>2 cm,或有溃疡且≤3 cm。
- A3级:未分化型、pT1a、无溃疡、≤2 cm。
- B级:分化型、pT1b(SM1)、≤3 cm。
- C级:非治愈性切除。
临床怎么用
- 作者认为内镜切除可推荐作为符合A1、A2、A3和B级早期胃癌患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We aimed to clarify the long-term outcomes of endoscopic resection (ER) for early gastric cancers (EGCs) based on pathological curability in a multicenter prospective cohort study. METHODS: We analyzed the long-term outcomes of 9054 patients with 10,021 EGCs undergoing ER between July 2010 and June 2012. Primary endpoint was the 5-year overall survival (OS). The hazard ratio for all-cause mortality was calculated using the Cox proportional hazards model. We also compared the 5-year OS with the expected one calculated for the surgically resected patients with EGC. If the lower limit of the 95% confidence interval (CI) of the 5-year OS exceeded the expected 5-year OS minus a margin of 5% (threshold 5-year OS), ER was considered to be effective. Pathological curability was categorized into en bloc resection, negative margins, and negative lymphovascular invasion: differentiated-type, pT1a, ulcer negative, ≤2 cm (Category A1); differentiated-type, pT1a, ulcer negative, >2 cm or ulcer positive, ≤3 cm (Category A2); undifferentiated-type, pT1a, ulcer negative, ≤2 cm (Category A3); differentiated-type, pT1b (SM1), ≤3 cm (Category B); or noncurative resections (Category C). RESULTS: Overall, the 5-year OS was 89.0% (95% CI, 88.3%-89.6%). In a multivariate analysis, no significant differences were observed when the hazard ratio of Categories A2, A3, and B were compared with that of A1. In all the pathological curability categories, the lower limit of the 95% CI for the 5-year OS exceeded the threshold 5-year OS. CONCLUSION: ER can be recommended as a standard treatment for patients with EGCs fulfilling Category A2, A3, and B, as well as A1 (UMIN Clinical Trial Registry, UMIN000005871).
引用
- Suzuki H, Ono H, Hirasawa T, et al. Long-term Survival After Endoscopic Resection For Gastric Cancer: Real-world Evidence From a Multicenter Prospective Cohort. Clin Gastroenterol Hepatol. 2022. PMID: 35948182. doi:10.1016/j.cgh.2022.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。